Chembio Diagnostics Inc. announced Friday that veteran health care executive John Sperzel had become its chief executive and president.
Sperzel succeeds Lawrence A. Siebert, who announced last fall that he would retire after more than a decade of leading the Medford-based manufacturer of rapid tests for HIV and syphilis. Sperzel took over on Thursday.
Sperzel has spent more than 25 years in the industry, most recenty serving as CEO of International Technidyne Corp. The Edison, N.J., business makes equipment that measures blood clotting and blood platelet reactivity after therapies.
"I look forward to building a strong Chembio brand and providing quality products and services to our global customers and partners," he said.
Chembio, a publicly traded business, has 210 employees and sales of about $30 million per year.
Sperzel's appointment was announced after the stock market opening. In early NASDAQ trading, Chembio shares were up more than 1 percent to $3.46.